Table 2.
Clinical and biochemical characteristics of patients with chronic hepatitis C treated with or without lithium carbonate.
| CHC Non-lithium treated |
CHC Lithium treated |
p value | |
|---|---|---|---|
| Patient numbers | 20 | 6 | |
| Age, median (range) | 46(19–71) | 45(20–58) | 0.1 |
| Male:Female | 7:13 | 2:4 | 0.1 |
| Course of disease (years) mean (±SD) | 17.83(±0.68) | 17.65 (±0.71) | 0.7 |
| Serum ALT (IU/L) mean (±SD) | 71.36(±7.34) | 58.17 (±8.53) | 0.2 |
| Serum TBIL (mmol/L) mean (±SD) | 37.64(±2.75) | 36.72(±4.61) | 0.6 |
| Serum ALB (g/L) mean (±SD) | 44.56(±3.78) | 46.91(±2.13) | 0.3 |
| HCV genotype | 0.4 | ||
| 1a | 6 | 2 | |
| 1b | 13 | 4 | |
| 6 | 1 | 0 | |
| Viral load (Log10IU/mL) mean (±SD) | 5.98(±0.71) | 6.23(±0.64) | 0.7 |
| Liver injury Knodell score mean (±SD) | 17.41(±0.62) | 6.63(±0.17) | <0.01 |
CHC, chronic hepatitis C; ALT, alanine transaminase; TBIL, total bilirubin; ALB, albumin.